학술논문

CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs
Document Type
article
Source
Journal of Clinical Investigation. 129(8)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Biotechnology
Rare Diseases
Orphan Drug
Pediatric Research Initiative
Infectious Diseases
Genetics
Cancer
Aetiology
2.1 Biological and endogenous factors
Animals
Carcinogenesis
Cell Line
Tumor
Cyclin E
Cyclin-Dependent Kinase 2
Female
Humans
Mice
Mice
SCID
Neoplasm Metastasis
Neoplasms
Experimental
Oncogene Proteins
Oncogene Proteins
Fusion
Proto-Oncogene Proteins c-ets
Sarcoma
Transcription
Genetic
Molecular genetics
Oncology
Medical and Health Sciences
Immunology
Biological sciences
Biomedical and clinical sciences
Health sciences
Language
Abstract
Transcription factor fusion genes create oncoproteins that drive oncogenesis and represent challenging therapeutic targets. Understanding the molecular targets by which such fusion oncoproteins promote malignancy offers an approach to develop rational treatment strategies to improve clinical outcomes. Capicua-double homeobox 4 (CIC-DUX4) is a transcription factor fusion oncoprotein that defines certain undifferentiated round cell sarcomas with high metastatic propensity and poor clinical outcomes. The molecular targets regulated by the CIC-DUX4 oncoprotein that promote this aggressive malignancy remain largely unknown. We demonstrated that increased expression of ETS variant 4 (ETV4) and cyclin E1 (CCNE1) occurs via neomorphic, direct effects of CIC-DUX4 and drives tumor metastasis and survival, respectively. We uncovered a molecular dependence on the CCNE-CDK2 cell cycle complex that renders CIC-DUX4-expressing tumors sensitive to inhibition of the CCNE-CDK2 complex, suggesting a therapeutic strategy for CIC-DUX4-expressing tumors. Our findings highlight a paradigm of functional diversification of transcriptional repertoires controlled by a genetically aberrant transcriptional regulator, with therapeutic implications.